Andrea Erriquez

Dr. Andrea Erriquez

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ASAntonella Scala
Antonella Scala
AEAndrea Erriquez
Andrea Erriquez
FVFilippo Maria Verardi
Filippo Maria Verardi
AMAndrea Marrone
Andrea Marrone
ESEnnio Scollo
Ennio Scollo
SBSimone Biscaglia
Simone Biscaglia
The present study investigates the prognostic value of the Syntax Score II 2020 corrected for flow-limiting lesions and its ability to better address treatment by benefit prediction among patients with left main or multivessel disease. We analyzed 1274 patients from the HALE-BOPP cohort and integrated the Syntax Score II 2020 with the result of the fractional flow reserve (FFR) evaluation. Absolute risk difference (ARD) between surgical and percutaneous revascularization was calculated for anatomic and functional Syntax Score II 2020 predicted mortality. The ARD allowed to stratify the population into two large categories: “coronary artery bypass graft (CABG) better” with ARD ≥ 4.5% and “CABG–percutaneous coronary intervention (PCI) equipoise” with ARD < 4.5%. The mean global anatomical Syntax Score was 15.5 ± 9.2, whereas the functional one was 9.5 ± 10 (p < 0.01). Using the anatomic Syntax Score II 2020, 881 patients had a CABG-PCI equipoise. This number increased to 1041 after considering only flow-limiting lesions by FFR (p < 0.001); therefore, 40% of CABG better patients were reclassified within the CABG-PCI equipoise category. Kaplan–Maier curves showed similar actual survival rates for patients originally with CABG-PCI equipoise and those reclassified, in both cases higher than those from CABG better patients (p < 0.01). The integration between Syntax Score II 2020 and physiology is feasible, and merging clinical, anatomic and functional data allows for better risk prediction and therapeutic guidance.

18 February 2020 in European Journal of Heart Failure
Verified
Journal Article
Open access
PDF file
MTMatteo Tebaldi
Matteo Tebaldi
ALAntonio Maria Leone
Antonio Maria Leone
SBSimone Biscaglia
Simone Biscaglia
ACAnnamaria Di Cesare
Annamaria Di Cesare
AEAndrea Erriquez
Andrea Erriquez
Gianluca CampoGianluca Campo
Gianluca Campo
Click on the article title to read more.

23 September 2025 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
AMAndrea Marrone
Andrea Marrone
AEAndrea Erriquez
Andrea Erriquez
FVFilippo Maria Verardi
Filippo Maria Verardi
ICIginio Colaiori
Iginio Colaiori
MCMarta Cocco
Marta Cocco
SBSimone Biscaglia
Simone Biscaglia

8 August 2025 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
JFJacopo Farina
Jacopo Farina
SKSant Kumar
Sant Kumar
Gianluca CampoGianluca Campo
Gianluca Campo
SBSimone Biscaglia
Simone Biscaglia
MZMarco Zuin
Marco Zuin
AEAndrea Erriquez
Andrea Erriquez

1 December 2021 in European Heart Journal Supplements
Verified
Journal Article
Open access
PDF file
AMAndrea Marrone
Andrea Marrone
FGFederico Gibiino
Federico Gibiino
ESEnnio Scollo
Ennio Scollo
MTMatteo Tebaldi
Matteo Tebaldi
SBSimone Biscaglia
Simone Biscaglia
Gianluca CampoGianluca Campo
Gianluca Campo
The study of coronary microcirculation has gained increasing consideration and importance in cath-lab. Despite the increase of evidence its use still remains very limited. QFR is a novel angio-based approach for the evaluation of coronary stenosis. The aim of our study was to use the QFR assessment in stable patients to recreate the IMR formula and to correlate the result of the two techniques. From 1 June 2019 to 29 February 2019, 200 patients with CCS and indication of coronary artery angiography and referred to the cath-lab of the University Hospital of Ferrara (Italy) were enrolled. After baseline coronary angiogram, quantitative flow ratio, fractional flow reserve and index of microcirculatory resistance evaluation were performed. Pearson correlation (r) between Angio-based index of microcirculatory resistance (A-IMR) and IMR 0.32 with R2 = 0.098, P = 0.03: McNemar test showed a difference between the two test of 6.82% with 95% CI from −12.05% to 22.89%, which is not significant (P = 0.60). Bland and Altman plot showed a mean difference of 23.3 (from −26.5 to 73.1). Sensitivity, specificity, NPV and PPV were 70%, 83.3%, 75% and 70% for A-IMR value > 44.2. The area under the ROC curve for A-IMR was 0.76 (95% CI: 0.61–0.88, P = 0.0003). We have validated for the first time the formula of the A-IMR, a tool for the calculation of microvascular resistance which does not require the use of pressure guides and the induction of hyperemia

9 November 2023 in European Heart Journal
Verified
Journal Article
Open access
PDF file
GPGraziella Pompei
Graziella Pompei
Gianluca CampoGianluca Campo
Gianluca Campo
RRR Ruggiero
R Ruggiero
DMD Maffeo
D Maffeo
FSF Sgura
F Sgura
ECEnrico Cerrato
Enrico Cerrato
Background: The SHERPA-MAGIC is an investigator-driven, multicenter, prospective, single-arm study that enrolled patients undergoing resorbable magnesium scaffold (RMS) implantation in 18 Italian centers. The results from the first 543 patients supported the safety and long-term performance of RMS in a real-world population. Purpose: The present post-hoc analysis aimed to assess differences in adverse events at patient-level (patient-oriented composite endpoints, POCE, defined as the composite of all-cause death, myocardial infarction -MI- and ischemia-driven coronary revascularization) at the longest follow-up between different subgroups of the final study population (n=543). Methods: We identified the subgroups according to different variables: age, sex, cardiovascular risk factors, clinical presentation, left ventricle ejection fraction, multivessel disease, multivessel PCI, and antiplatelet therapy. If the analysis highlighted a subgroup of patients at higher risk of adverse events, to understand if this finding is related to RMS implantation or to the characteristic itself, a propensity score matched analysis was conducted comparing patients of the SHERPA-MAGIC study with a matched cohort of patients receiving second generation drug eluting stent. The endpoint for the comparison between the two matched cohorts was POCE. Results: The mean age of the final study population was 56±9 years. 433 (78%) patients were men, and the most common clinical presentation was MI (n=402, 74%). At the median follow-up of 3.5 [2.6-4.3] years, the cumulative occurrence of the primary endpoint (vessel-oriented composite endpoints, VOCE, including cardiac death, target vessel MI, and ischemia-driven target vessel revascularization) was 37 (5.8%, 95%CI 4.1%-7.9%) and 54 (9.9%, 95% CI 7.5%-12.7%) patients met criteria for POCE. There was no significant difference among POCE in the subgroup analysis (Figure 1), with the exception of patients with MI as clinical presentation. As compared to patients admitted for chronic coronary syndrome, MI patients showed a significantly higher POCE rate (11.4 vs 5.6%, CI 8.5-14.9, p=0.04). Therefore, a propensity score matched analysis was conducted comparing MI patients of the SHERPA-MAGIC study with a matched cohort of MI patients from the Acute coRonary sYndrOmes proSpective regisTry Of Ferrara (ARYOSTO) study (NCT02438085) treated with second-generation DES. We did not find significant differences in the cumulative occurrence of POCE between SHERPA MAGIC and ARYOSTO (11.4% vs. 12.5% respectively, p=0.71) (Figure 2). Conclusions: The present analysis confirmed the safety and effectiveness of RMS across several subgroups of patients stratified by clinical and procedural characteristics. We found that MI patients had an higher occurrence of POCE, but this was not related to RMS implantation. Indeed, a similar MI population treated with second generation DES showed the same long-term outcome.Fig 1POCE difference between subgroupsFig 2Propensity matched MI populations